Seganserin

This classification denotes a serotonin antagonist with the molecular formula C29H27F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 197HL4EZCC, chemically known as 4h-pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(bis(4-fluorophenyl)methylene)-1-piperidinyl)ethyl)-2-methyl-, dihydrochloride but generally known as seganserin, which bears US NIH Compound Identifier 71767. European Medicines Agency schedules Seganserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10472MIG. The term SEGANSERIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). SEGANSERIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule seganserin under HS 29335995 and SITC 51576. As of Q4 2014, SEGANSERIN remains the US FDA Preferred Term for this commodity. Seganserin bears US NLM identifiers UMLS ID C0074270 and NCI Concept Code C76967. SMILES: Fc1ccc(C(=C2\CCN(CC2)CCc2c(nc3n(c2=O)cccc3)C)/c2ccc(F)cc2)cc1.